Shatavari and menopause symptoms

What 4 graded rows on shatavari agree on for menopause symptoms, and where they differ. Counted side by side, never averaged.

What the rows agree on

Each block and row is one graded row from the Shatavari page, with its PubMed record.

Your question

Shatavari and menopause symptoms

4 rows · 328 people

They agree: all 4 rows found an improvement.

No difference
Each block is one evidence row, sized by how many people it enrolled, with its grade inside.
  • Grade B× 4
Rows
4
Trials
4
People
328

What the rows share

From the rows

The best-graded row, grade B, is a randomized trial of 125 people (2025) and found an improvement.

The rows run from 60 to 125 people, published from 2024 to 2026: 4 single studies.

The rows

4 improved
  1. Grade BMenopause Rating Scale · Improved

    RCT · n 125 · 2025 · Women aged 45–65 with menopausal symptoms in India

    300 mg/day · 8 weeks

    At 8 weeks, total symptom scores improved more with shatavari than placebo (p < 0.0001); the abstract reports a further gain with shatavari plus ashwagandha, but the full-text table shows the same week-8 total change for both active arms. Quality-of-life scores did not differ between groups.

    Row on the Shatavari page · PubMed 41394012 (opens PubMed)

  2. Grade BPerimenopause symptom and stress scores · Improved

    RCT · n 73 · 2025 · Women with perimenopausal symptoms in India

    300 mg/day · 8 weeks

    Menopause Rating Scale, stress and hot-flash scores improved more than with placebo; estradiol, FSH and T3 rose; liver and kidney tests were unchanged.

    Row on the Shatavari page · PubMed 41209045 (opens PubMed)

  3. Grade BMenopause symptoms and quality of life · Improved

    RCT · n 70 · 2024 · Women with menopausal symptoms in India

    500 mg/day (250 mg twice daily) · 8 weeks

    Hot flashes, night sweats, sleep, anxiety, vaginal dryness and libido improved more than with placebo; no significant adverse events.

    Row on the Shatavari page · PubMed 38725785 (opens PubMed)

  4. Grade BMenopause-specific quality of life and hormones · Improved

    RCT · n 60 · 2026 · Pre-, peri- and postmenopausal women (mean age 50)

    100 mg/day · 8 weeks

    MENQOL scores fell 42.8% more than with placebo, across vasomotor, psychosocial, physical and sexual domains; estradiol rose (+36% vs −2%) and FSH fell (−38% vs +13%). Liver tests and blood chemistry stayed normal.

    Row on the Shatavari page · PubMed 42571384 (opens PubMed)

Educational only. Not medical advice. Some links earn us a commission: kymatahealth.com/affiliate-disclosure.